Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
52 hedge funds and large institutions have $41.2M invested in Oncternal Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 5 closing their positions.
580% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 5
481% more capital invested
Capital invested by funds: $7.1M → $41.2M (+$34.1M)
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
126% more funds holding
Funds holding: 23 → 52 (+29)
25% more call options, than puts
Call options by funds: $320K | Put options by funds: $256K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.44M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.26M |
| 3 |
6CM
683 Capital Management
New York
|
+$2.31M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.19M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.24M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.04M |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$1.19M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$331K |
| 5 |
Renaissance Technologies
New York
|
-$155K |
ONCT Hedge Fund Activity: Q4 2020 in Review
52 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2020, worth a combined $41.2M — up 481% from $7.1M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ONCT positions and 5 closed out — a net gain of 29 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.44M. The largest seller was Armistice Capital, exiting entirely with an estimated $2.24M sold.
- 52 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2020, up from 23 in Q3 2020.
- Funds reported $41.2M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2020, up 481% quarter-over-quarter.
- 34 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2020 and 5 closed out, a net change of +29 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2020 was Vanguard Group, an estimated $4.44M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2020 was Armistice Capital, an estimated $2.24M sold.
Based on aggregated 13F filings for Q4 2020.